A Retrospective Pharmacogenomics Research of EGFR-TKIs,Gefitinib and Erlotinib, in NSCLC Patients Treatment
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 200
Summary
- Conditions
- EGFR-TKI Resistant Mutation
- EGFR-TKI Sensitizing Mutation
- Germline Mutations
- Non - Small Cell Lung Cancer NSCLC
- Somatic Mutation
- Type
- Observational
- Design
- Observational Model: Case-OnlyTime Perspective: Retrospective
Participation Requirements
- Age
- Between 18 years and 85 years
- Gender
- Both males and females
Description
The ADME-associated SNPs included are CYP3A4,CYP3A4,CYP1A1,CYP2D6, ABCB1,ABCG2 and so on .The somatic mutations included are EGFR ,K-RAS ,ALK and so on
The ADME-associated SNPs included are CYP3A4,CYP3A4,CYP1A1,CYP2D6, ABCB1,ABCG2 and so on .The somatic mutations included are EGFR ,K-RAS ,ALK and so on
Tracking Information
- NCT #
- NCT01994057
- Collaborators
- Not Provided
- Investigators
- Study Chair: Min Huang, Professor school of pharmaceutical sciences , SunYat-senU